Last reviewed · How we verify

Propofol and dexmedetomidine

Yonsei University · FDA-approved active Small molecule Quality 5/100

Propofol and dexmedetomidine is a Small molecule drug developed by Yonsei University. It is currently FDA-approved.

At a glance

Generic namePropofol and dexmedetomidine
SponsorYonsei University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Propofol and dexmedetomidine

What is Propofol and dexmedetomidine?

Propofol and dexmedetomidine is a Small molecule drug developed by Yonsei University.

Who makes Propofol and dexmedetomidine?

Propofol and dexmedetomidine is developed and marketed by Yonsei University (see full Yonsei University pipeline at /company/yonsei-university).

What development phase is Propofol and dexmedetomidine in?

Propofol and dexmedetomidine is FDA-approved (marketed).

Related